Cancer drug development company | Taivex Therapeutics Corporation https://validator.w3.org/feed/docs/rss2.html cookie-policy T-1301 T-1201 T-1101 Taivex Therapeutics Corporation T-1501 NHRI Enters Technology Transfer Agreement of T-1501 (DBPR186) with Taivex Therapeutics Corp. Groundbreaking Cancer Treatments T-1201 and T-1301 to be Presented at WCC-2024 First in the worldwide! Oral powder T-1101 approved by the US FDA to start Phase I clinical study T-1201 (DBPR115) Technique transfer from National Health Research Institute (NHRI) T-1101 OPC approved by the TFDA to start Phase I clinical study T-1201 get 2017 Taipei Biotech Award_ Technology Transfer Gold Medal Award A major milestone for cancer drug development in Taivex! T-1101 OPC initiates Phase I clinical study Dr. Lun Kelvin Tsou receiving the 14th Tien Te Lee Biomedical Young Scientists Award T-1301, a multi-targeted anti-cancer developmental drug candidate, is licensed from The National Health Research Institutes to Taivex Therapeutics Corp. Enrollment of oral powder T-1101 OPC phase trial has completed in Taiwan T-1101 capsule approved by the FDA to start Phase I clinical study T-1101 capsule approved by the TFDA to start Phase I clinical study T-1101 capsule initiated Phase I clinical study Taivex’s anti-cancer oral drug T-1201 received Phase I IND approval by the US FDA to enter clinical development. Taivex’s anti-cancer oral drug T-1201 received Phase I IND approval by the Taiwan FDA to conduct Phase I clinical trial. Taivex’s anti-cancer oral drug T-1301 received Phase I IND approval by the US FDA to enter clinical development Announces the Initiation of Phase I Clinical Trial of T-1201, A Novel Small-molecule Drug Conjugate (SMDC), in Taiwan Taivex’s anti-cancer oral drug T-1301 received Phase I IND approval by the Taiwan FDA to conduct Phase I clinical trial T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021 T-1101 be invited for an oral presentation at the 19th Annual Congress of International Drug DiscoveryScience & Technology (IDDST-2023) T-1101 Accepted for Poster Presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, Highlighting Clinical Promise and Global Recognition Our Products About Taivex Taivex’s ‘s T-1101 and T-1201 Invited to Present Study Progress at KSMO 2024 Annual Meeting T-1101 Accepted for Online Publication at the 2025 ASCO Annual Meeting, Showcasing Innovative Mechanism and Clinical Potential News T-1201 Phase I study design present at 2025 ASCO T-1101 Receives FDA Approval to Advance to Phase II Clinical Trial, Marking a Significant Milestone T-1101 Receives TFDA Approval for Phase II Clinical Trial, Advancing Development Milestone 全站設定，勿刪！ T-1101 granted the MOEA 2011 Breakthrough Innovation of the Year Award Enrollment of the first patient for T-1301 Phase I clinical trial was achieved in August, 2022. Taivex Therapeutics’ three clinical projects have been selected to present their project progress at the AACR Annual Meeting 2024 Taivex Therapeutics participated the 2024 BIO-Europe Spring for the opportunities of international collaboration Contact Us Taivex Therapeutics Corporation will attend Bio Asia-Taiwan 2024